Vinge assisted Boliden on the deal. Boliden has entered into a definitive agreement with Lundin Mining to acquire the Neves-Corvo mine in Portugal and the Zinkgruvan...
You must be a Standard 1 Year member to access this content.
Vinge advised Apotea on the deal. Apotea AB (publ) completed its listing on Nasdaq Stockholm. The offering price was SEK 58 per ordinary share, corresponding to a...
You must be a Standard 1 Year member to access this content.
Vinge advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission,...
You must be a Standard 1 Year member to access this content.
Vinge advised Cinclus Pharma on the deal. Cinclus Pharma Holding AB (publ) secured an offering of new ordinary shares and listing on Nasdaq Stockholm. The offering...
You must be a Standard 1 Year member to access this content.
Vinge advised Tobii AB on the offering. Tobii AB (publ) finalized its rights issuance of ordinary shares which will provide Tobii with issue proceeds of approximately...
You must be a Standard 1 Year member to access this content.
Vinge assisted Tobii AB on the deal. Tobii AB completed the acquisition of the AutoSense business from Xperi Inc. The transaction accelerates Tobii’s path to leadership...
You must be a Standard 1 Year member to access this content.
Vinge has advised Scandic Hotels Group AB on the deal. Scandic Hotels Group AB (publ) repurchased convertible bonds. In total, convertible bonds with an aggregate nominal amount...
You must be a Standard 1 Year member to access this content.
Vinge advised Egetis Therapeutics AB on the deal. Egetis Therapeutics AB (publ), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization...
You must be a Standard 1 Year member to access this content.
Vinge advised Immunovia on the deal. Immunovia AB (publ) has resolved on a new issue of shares of approximately SEK 202.2 million with preferential right for...
You must be a Standard 1 Year member to access this content.
Vinge has advised Egetis Therapeutics AB on the deal. Egetis Therapeutics AB (publ), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization...
You must be a Standard 1 Year member to access this content.
Vinge has advised Hansa Biopharma on the deal. Hansa Biopharma announced directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs....
You must be a Standard 1 Year member to access this content.
Lund Elmer Sandager and Vinge assisted Lagercrantz Group AB on the deal. Lundgrens advised Maj Invest Equity 4 K/S and the minority shareholders of PcP Corporation...
You must be a Standard 1 Year member to access this content.
